NPM1 FLT3 CEBPA Genetic Test - $488 USD | Comprehensive Leukemia Mutation Analysis | Available Across USA
Myeloproliferative Leukemia Mutation Screening MPL S505N W515L Test - $168 USD Price in USA | GGC DNA Myeloproliferative Leukemia Mutation Screening MPL S505N W515L Original price was: $226.Current price is: $168.
IGHM Gene Agammaglobulinemia Type 1 NGS DNA Test | $500 USD | USA Genetic Testing | Comprehensive Diagnosis IGHM Gene Agammaglobulinemia Type 1 Autosomal Recessive NGS Genetic DNA Test Original price was: $700.Current price is: $500.
Sale!

NPM1 FLT3 CEBPA Genetic Mutation Test

Original price was: $650.Current price is: $488.

-25%

The NPM1 FLT3 CEBPA genetic test is a comprehensive molecular analysis that detects critical mutations associated with acute myeloid leukemia (AML). This advanced diagnostic tool utilizes Sanger sequencing technology to identify specific genetic alterations in the NPM1, FLT3, and CEBPA genes, which play crucial roles in leukemia development and progression. The test provides essential information for accurate diagnosis, prognosis assessment, and treatment planning. Patients with unexplained fatigue, recurrent infections, abnormal bleeding, or bruising should consider this test. Results help guide targeted therapy decisions and predict treatment response. The test is available for $488 USD (regularly $650) with results in 7-8 days using bone marrow or peripheral blood samples.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

NPM1 FLT3 CEBPA Genetic Mutation Test

Comprehensive Introduction to Genetic Leukemia Testing

The NPM1 FLT3 CEBPA genetic test represents a cutting-edge molecular diagnostic approach for acute myeloid leukemia (AML) management. This comprehensive analysis examines three critical genes that significantly influence leukemia behavior, treatment response, and patient outcomes. By detecting specific mutations in these genes, healthcare providers can develop personalized treatment strategies that maximize effectiveness while minimizing unnecessary side effects.

Genetic testing has revolutionized leukemia care by moving beyond traditional classification systems to provide molecular-level insights. The NPM1 FLT3 CEBPA panel specifically targets mutations that have demonstrated clinical significance in predicting disease course and guiding therapeutic decisions. Understanding these genetic markers enables more precise risk stratification and treatment selection.

What Does the Test Measure and Detect?

This sophisticated genetic panel utilizes Sanger sequencing technology to identify specific mutations in three key leukemia-associated genes:

NPM1 Gene Mutations

  • Detects nucleophosmin 1 gene mutations affecting nuclear-cytoplasmic shuttling
  • Identifies specific insertion mutations in exon 12
  • Helps classify AML subtypes with distinct clinical behaviors

FLT3 Gene Mutations

  • Screens for internal tandem duplications (ITD) in the FLT3 gene
  • Detects tyrosine kinase domain (TKD) point mutations
  • Identifies mutations associated with aggressive disease and poor prognosis

CEBPA Gene Mutations

  • Analyzes CCAAT/enhancer-binding protein alpha gene mutations
  • Detects both N-terminal and C-terminal mutations
  • Identifies favorable prognosis markers in specific AML subtypes

Who Should Consider This Genetic Test?

This comprehensive genetic analysis is recommended for individuals experiencing symptoms suggestive of acute myeloid leukemia or those with confirmed AML diagnosis requiring detailed molecular characterization.

Symptoms and Clinical Indications

  • Unexplained fatigue, weakness, or persistent tiredness
  • Frequent infections or prolonged recovery from illnesses
  • Unexplained bruising, bleeding, or petechiae
  • Bone pain or tenderness
  • Unintentional weight loss and loss of appetite
  • Fever without apparent infection
  • Enlarged lymph nodes, liver, or spleen
  • Abnormal complete blood count results
  • Newly diagnosed AML patients for risk stratification
  • Patients considering targeted therapy options

Significant Benefits of Genetic Testing

Undergoing the NPM1 FLT3 CEBPA genetic test provides numerous advantages for both patients and healthcare providers:

Personalized Treatment Planning

  • Enables selection of targeted therapies based on specific mutation profiles
  • Helps avoid ineffective treatments and unnecessary side effects
  • Guides decisions regarding chemotherapy intensity and duration

Accurate Prognosis Assessment

  • Provides reliable risk stratification for disease progression
  • Helps predict treatment response and potential complications
  • Supports informed discussions about treatment goals and expectations

Comprehensive Disease Monitoring

  • Establishes baseline mutation status for future comparison
  • Enables detection of minimal residual disease after treatment
  • Supports early intervention if disease recurrence occurs

Understanding Your Test Results

Interpreting genetic test results requires careful consideration by qualified healthcare professionals. Here’s general guidance on what different results may indicate:

Mutation Detection and Clinical Significance

  • NPM1 Mutations: Generally associated with favorable prognosis when FLT3-ITD negative
  • FLT3-ITD Mutations: Often indicate aggressive disease requiring intensive therapy
  • CEBPA Mutations: Typically predict favorable outcomes with standard treatment
  • Combined Mutations: Complex patterns require specialized interpretation

Result Interpretation Framework

  • Positive results indicate specific genetic alterations requiring targeted management
  • Negative results suggest standard risk classification and treatment approaches
  • Variant of uncertain significance may require additional testing or monitoring
  • All results should be discussed with your hematologist or oncologist

Test Information and Pricing

Test Parameter Details
Test Name NPM1 FLT3 CEBPA Genetic Mutation Test
Discount Price $488 USD
Regular Price $650 USD
Turnaround Time 7-8 Days
Sample Type Bone Marrow / Peripheral Blood (Transport Immediately)
Test Components EDTA Vacutainer (2ml)
Testing Method Sanger Sequencing
Specialty Hematology, Oncology, Genetics

Pre-Test Instructions and Requirements

The NPM1 FLT3 CEBPA genetic test requires a doctor’s prescription for most cases. However, prescription requirements do not apply for surgery preparation, pregnancy-related testing, or individuals planning international travel. Our experienced genetic counselors are available to discuss testing indications and answer any questions you may have about the procedure.

Nationwide Testing Availability

We proudly serve patients across the United States with convenient testing locations in all major metropolitan areas. Our network includes specialized collection centers in:

  • New York City and surrounding areas
  • Los Angeles and Southern California
  • Chicago and the Midwest region
  • Houston and Texas metropolitan areas
  • Phoenix and Arizona communities
  • Philadelphia and the Northeast corridor
  • All other major US cities and regions

Take Control of Your Health Today

Don’t wait to get the critical genetic information needed for optimal leukemia management. Our comprehensive NPM1 FLT3 CEBPA genetic test provides the molecular insights necessary for personalized treatment decisions and improved outcomes.

Call or WhatsApp us today at +1(267) 388-9828 to schedule your test or speak with our genetic specialists. We’re here to help you navigate your healthcare journey with confidence and clarity.

Early genetic testing can make a significant difference in treatment planning and disease management. Contact us now to learn more about how this advanced genetic analysis can benefit your specific situation and take the first step toward personalized leukemia care.

SKU: 2118d8a1b700 Category:

Related products